The FDA approved Rukobia, developed by ViiV Healthcare, majority-owned by GlaxoSmithKline plc (GSK) on July 2, 2020, for the treatment of HIV infection.Rukobia (fostemsavir) is a novel attachment inhibitor used in combination with other antiretroviral therapies for heavily treatment-experienced (HTE) patients with HIV-1 infection, who are resistant to multiple drugs.HTE patients, who account for 6% of the adults with HIV in the U.S., are at the risk of progressing to AIDS. Analysts expect the drug to bring in sales of about $400 million.Rukobia was submitted to the European Medicines Agency for approval in January this year.